Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Four years after starting semaglutide, patients maintained an average weight loss of 10% of their body weight, a peer-reviewed 2024 study funded by Novo Nordisk found. Doctors say the drug’s ...

Don't miss out on the headlines from Weight Loss. Followed categories will be ... the results of a major clinical trial that showed semaglutide 2.4 mg (sold as Wegovy) reduced cardiovascular ...

Some of the effects of weight loss are improved energy, fertility, mental health, and sleep. This weight loss can also reduce your risk for conditions like heart disease and diabetes. 1.